SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) was the target of a significant drop in short interest in the month of September. As of September 15th, there was short interest totaling 765 shares, a drop of 88.5% from the August 31st total of 6,640 shares. Based on an average daily volume of 43,794 shares, the days-to-cover ratio is presently 0.0 days.
SAB Biotherapeutics Stock Performance
SABSW opened at $0.01 on Friday. The company has a 50-day moving average price of $0.02 and a 200 day moving average price of $0.02. SAB Biotherapeutics has a twelve month low of $0.00 and a twelve month high of $0.20.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Further Reading
- Five stocks we like better than SAB Biotherapeutics
- Cintas Raises Guidance as a Major Catalyst Moves Closer
- 3 Space Stocks to Watch as SpaceX Reshapes the Launch Market
- Dave’s Success Has Investors Split
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
